TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04026113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Oral capsule (For participants who do not wish to take the dose as a capsule, a sprinkled dose may be prepared)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Oral capsule (For participants who do not wish to take the dose as a capsule, a sprinkled dose may be prepared)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Oral capsule (For participants who do not wish to take the dose as a capsule, a sprinkled dose may be prepared)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo
Study: NCT02732275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-3201b
Description: DS-3201 to be administered orally once daily in each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-3201b
Description: DS-3201 to be administered orally once daily in each 28-day cycle at the recommended dose for expansion.
Study: NCT04192565

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ColubrisMX Endoluminal Surgical (ELS) System
Description: Robotic Transanal Endoluminal Resection of Colorectal Lesions using the ColubrisMX Endoluminal Surgical (ELS) System
Study: NCT03037931

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric Carboxymaltose
Description: Intravenous Iron

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline Solution
Study: NCT04140019

Intervention type: DIAGNOSTIC_TEST
Intervention: CMR
Description: Early CMR with adenosine stress/rest perfusion before invasive coronary angiography.
Study: NCT04386291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anxiety Reduction Training
Description: Educational material will be provided every two weeks that address different aspects of anxiety and cognitive-behavioral approaches to reduce anxiety and stress.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anxiety Reduction Training
Description: Educational material will be provided every two weeks that address different aspects of anxiety and cognitive-behavioral approaches to reduce anxiety and stress.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Anxiety Reduction Training
Description: Educational material will be provided every two weeks that address different aspects of anxiety and cognitive-behavioral approaches to reduce anxiety and stress.
Study: NCT04556292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC10914
Description: SC10914 400mg tid
Study: NCT00271960

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CenteringPregnancy
Description: Following the initial intake into obstetric care in the usual manner, participants will be invited to join with 8 to 12 other women/couples/teens with similar due dates, meeting together regularly during their pregnancy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CenteringPregnancy
Description: Following the initial intake into obstetric care in the usual manner, participants will be invited to join with 8 to 12 other women/couples/teens with similar due dates, meeting together regularly during their pregnancy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CenteringPregnancyPlus
Description: CenteringPregnancyPlus is a modified program that integrated HIV/STD prevention components with the group prenatal care model. Participants will learn skill-building in the areas of efficacy, risk assessment, negotiation skills and prevention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants will receive usual prenatal care.
Study: NCT02492022

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic L008-1
Description: Dosing regimen of 2 capsules daily, once per day, for 14 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic L008-2
Description: Dosing regimen of 2 capsules daily, once per day, for 14 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosing regimen of 2 capsules daily, once per day, for 14 weeks
Study: NCT01015859

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacing mode
Description: To determine which mode (DDD vs AAI SafeR)minimizes ventricular pacing
Study: NCT04340791

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increased proportion of lower energy density items
Description: The proportion of lower energy density vs. higher energy density items will be reversed (67% lower - 33% higher) relative to the default proportion condition (D and DL) (33% lower - 67% higher). Lower energy density items will be defined as lower energy density ≤ median of energy density distribution within a food category.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increased proportion of lower energy density items
Description: The proportion of lower energy density vs. higher energy density items will be reversed (67% lower - 33% higher) relative to the default proportion condition (D and DL) (33% lower - 67% higher). Lower energy density items will be defined as lower energy density ≤ median of energy density distribution within a food category.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Labelling
Description: When energy density of an item ≤ median of ED distribution within a food category, healthier choice badges will be added to the food item pictures on the online supermarket. Instructions when logging-into the platform will introduce the badges to the participants: In the online supermarket, the green tick allows you to see which products (e.g. muesli) in each product category (e.g. cereals) are healthier choices with fewer calories per gram than most other products in the same category.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Labelling
Description: When energy density of an item ≤ median of ED distribution within a food category, healthier choice badges will be added to the food item pictures on the online supermarket. Instructions when logging-into the platform will introduce the badges to the participants: In the online supermarket, the green tick allows you to see which products (e.g. muesli) in each product category (e.g. cereals) are healthier choices with fewer calories per gram than most other products in the same category.
Study: NCT00134745

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: estradiol
Description: tablets, 2 mg day 1 through day 22 of the menstrual cycle for 5 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estradiol
Description: tablets, 2 mg day 1 through day 22 of the menstrual cycle for 5 years
Study: NCT02407990

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BGB-A317
Description: In the dose escalation part, the dose levels were escalated following a modified 3+3 dose escalation scheme. In the scheduled exploration part, participants were assigned to doses and dose schedules. In the fixed dose exploration part, participants were assigned to dose group(s) not to exceed the maximum tolerated dose. In the dose expansion part, participants were assigned to different groups based on their tumor type.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BGB-A317
Description: Participants were assigned to different groups based on their tumor types
Study: NCT02576301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 1 - OXi4503
Description: Determination of MTD of OXi4503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 1 - OXi4503 + cytarabine
Description: Determination of MTD of the combination of OXi4503 + cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 2 - OXi4503 + cytarabine
Description: Safety and efficacy of the combination of OXi4503 + cytarabine in subjects with AML

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 2 - OXi4503 + cytarabine
Description: Safety and efficacy of the combination of OXi4503 + cytarabine in subjects with MDS
Study: NCT03429829

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flairesse varnish
Description: Flairesse is applied to enamel and dentine as protective varnish to prevent caries formation and to promote remineralization of initial caries. It is also used in the treatment of hypersensitive teeth by sealing dentin tubules and hypersensitive areas at the neck of the tooth and exposed root dentine. Flairesse varnish contains xylitol and fluoride (22,600 ppm). Both components have been well established for oral health by reducing caries prevalence and incidences.~During the application, children sat upright; their teeth were first cleaned and dried with cotton wool rolls. After mixing the fluoride varnish, it was applied as a thin layer to all surfaces of the lower and upper dentition, including proximal surfaces (using floss in case of tight contact points) as well as pits and fissures (using a small brush that was provided together with the varnish by the manufacturer). Children were advised not to drink or eat directly after the application, while this could not be controlled.
Study: NCT00201786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: Pentostatin is given at a dose of 1.5 mg/m2/day IV x 3 consecutive days. Each IV infusion of pentostatin will be administered over 20-30 minutes in 100-250 ml of D5W or NS. To prevent nephrotoxicity, patients will also receive 500 ml normal saline as pre- and post drug hydration (total 1000 ml).
Study: NCT00734097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Description: Once a day

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Exam
Description: every visit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Questionnaires
Description: every visit

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pregnancy test, if applicable
Description: as needed
Study: NCT02511912

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: V-Wave
Description: The V-Wave shunt implantation procedure is a standard femoral venous access and inter-atrial septal puncture intervention. The shunt is placed through the Fossa Ovalis.
Study: NCT03929744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Administered orally.
Study: NCT01946763

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pre operative education
Description: Patients will be randomized in 2 groups (G1: educated, G2:non-educated) In the operating room and before starting anesthesia G1 will receive a pre operative education about anesthesia emergence, recovery and extubation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pre operative education
Study: NCT00484289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Vials (250 mg/vial), Intravenous, Weight-tiered dose of abatacept (equivalent to 10 mg/kg) based on their body weight at the enrollment visit; 500 mg for participants \< 60 kg, 750 mg for participants 60 to 100 kg and 1,000 mg for participants \> 100 kg, administered over a period of approximately 30 minutes at week 0, 2, 4 and every 4 weeks thereafter, until approved in Japan and was continued as a post-marketing study until the completion of the shift to a commercially available product.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Vials (250 mg/vial), Intravenous, Weight-tiered dose of abatacept (equivalent to 10 mg/kg) based on their body weight at the enrollment visit; 500 mg for participants \< 60 kg, 750 mg for participants 60 to 100 kg and 1,000 mg for participants \> 100 kg, administered over a period of approximately 30 minutes at week 0, 2, 4 and every 4 weeks thereafter, until approved in Japan and was continued as a post-marketing study until the completion of the shift to a commercially available product.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Vials (250 mg/vial), Intravenous, Weight-tiered dose of abatacept (equivalent to 10 mg/kg) based on their body weight at the enrollment visit; 500 mg for participants \< 60 kg, 750 mg for participants 60 to 100 kg and 1,000 mg for participants \> 100 kg, administered over a period of approximately 30 minutes at week 0, 2, 4 and every 4 weeks thereafter, until approved in Japan and was continued as a post-marketing study until the completion of the shift to a commercially available product.
Study: NCT01546636

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hypocapnic group
Description: Patients will be ventilated to an ETCO2 of 30-32 mm Hg.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normocapnic group
Description: Patients will be ventilated to an ETCO2 of 40-42 mm Hg
Study: NCT03062579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be intravenously administered as the dosage of 8 mg/kg every 4 weeks, 6 weeks if possible, without concurrent other immunosuppressive treatments.
Study: NCT04386291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kundalini Yoga and Anxiety Reduction Training
Description: Daily practice of Kundalini Yoga (light stretching, breathing exercises, and meditation) guided by on-line video instruction, as well as the biweekly anxiety reduction psychoeducation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation and Anxiety Reduction Training
Description: Daily practice of meditation (muscle relaxation, breathing, and meditation) guided by on-line video instruction, as well as the biweekly anxiety reduction psychoeducation.
Study: NCT04434768

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UMSC01
Description: There will be one dose of IV administration in patients with acute ischemic stroke, or one dose of IV administration followed by low or high doses of IA infusion for acute ischemic stroke with or without bridging therapy (i.e. Intravenous rt-PA thrombolysis or intraarterial thrombectomy) with 12 months of follow up after the first treatment.
Study: NCT00192647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFN alfa-2a
Description: PEG-IFN alfa-2a will be administered once weekly for 48 weeks, at doses specified in respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFN alfa-2a
Description: PEG-IFN alfa-2a will be administered once weekly for 48 weeks, at doses specified in respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin 1000 or 1200 mg orally daily in divided doses, with the dose determined based on body weight, for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin 1000 or 1200 mg orally daily in divided doses, with the dose determined based on body weight, for 48 weeks.
Study: NCT04682444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enisamium Iodide
Description: Patients ingested Amizon tablets after meal without chewing as follows: 2 tablets (total dose 0.5 g) 3 times a day, for 7 days. Each tablet contains 0.25 g of Nmethyl- 4-N-methyl-4-benzylcarbamidopyridinium iodide (INN enisamium iodide).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients ingested placebo tablets after meal without chewing in the dose 0.5 g (2 tablets), 3 times a day, for 7 days.
Study: NCT02992821

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bed-side pocket size ultrasound imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High frame rate tracking doppler
Study: NCT01859273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth
Description: mHealth prototype system consisting of electronic medication tray, blood pressure cuff and smart phone
Study: NCT02110615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary Care Practice Changes
Description: The clinical intervention components included (1) advanced training on clinical quality improvement and obesity prevention, assessment, management; (2) computerized, point-of-care decision support tools for clinicians; (3) implementation of multi-disciplinary weight management programs within the community health centers, e.g. Healthy Weight Clinics (HWC); (4) integrating community health workers into the primary care and HWC teams; and (5) health center environmental changes to support behavior change modification.
Study: NCT02905071

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: filling of Serenat at baseline (T1)
Description: Patients who consult occupational doctor complete the serenat questionnaire.The time taken to complete the serenat scale is about 5 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serenat at baseline T1 and 3 others questionnaires
Description: Subjects who consult occupational doctor complete the 4 questionnaires.The time taken to complete the 4 questionnaires is about 15 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serenat at baseline T1 and 3 others questionnaires
Description: Subjects who consult occupational doctor complete the 4 questionnaires.The time taken to complete the 4 questionnaires is about 15 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: filling of Serenat, HADS, STAY-Y and BDI at baseline T1
Description: Patients who consult a psychiatrist in a stress anxiety unit complete the 4 questionnaires.
Study: NCT00697333

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: restriction of radiotherapy to FDG-PET positive areas only
Description: Restriction of target volumes to areas positive in positron emission tomography using fluoro-deoxy-glucose
Study: NCT02687893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Subjects will exercise on a treadmill for 45 minutes twice during the intervention week. Subjects will exercise at a fixed intensity level to a target heart rate (±10%) based on the heart rate achieved at 60% of their VO2max determined at screening. The speed and grade of the treadmill will be adjusted by trained research personnel with a goal of keeping participants within their target heart rate range for the entire 45 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Subjects will participate in resistance exercises for 45 minutes twice during the intervention week. Subjects will perform multiple-joint exercises with slow to moderate lifting velocity, for 1-3 sets per exercise at a weight that can be lifted for 8-12 repetitions (\~60-80% of 1-repetition max). The exercises may include leg press, bench press, leg extension, leg flexion and seated row. Subjects will perform the exercises through the full range of motion. Between each set of repetitions, there would be a 2 minute rest period. The duration of the exercise testing would be approximately 45 minutes.
Study: NCT02275832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 % Minoxidil lotion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05589168

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Triage nurse
Description: Triage nurse joins 911 call

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No triage nurse
Description: Triage nurse does not join 911 call (business as usual)
Study: NCT03341767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofazimine
Description: 50 or 100 mg micronized Clofazimine suspended in an oil-wax base in a gelatin capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofazimine
Description: 50 or 100 mg micronized Clofazimine suspended in an oil-wax base in a gelatin capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oil-wax in gelatin capsule
Study: NCT04331587

Intervention type: DEVICE
Intervention: BF-P190 4 mm thin bronchoscope
Description: * EVIS EXERA III Bronchofiberviedoscopes~* Olympus

Intervention type: DEVICE
Intervention: BF-MP190F 3 mm ultrathin bronchoscope
Description: * EVIS EXERA III Bronchofiberviedoscopes~* Olympus

Intervention type: DEVICE
Intervention: Radial ultrasound probe (UM S20-17S)
Description: -Olympus

Intervention type: DEVICE
Intervention: PeriView FLEX 21G Single Use Aspiration Needle
Description: * NA-403D-2021~* Gyrus ACMI, Inc.
Study: NCT03636282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hockey FIT Program (Immediate Delivery)
Description: Hockey FIT is comprised of a 3-Month Active Phase and a 9-Month Minimally-Supported Phase.~Active Phase: 12 weekly, 90-minute group-based sessions consisting of classroom-based education and exercise. Outside of sessions, participants follow their individualized lifestyle prescriptions for healthy eating, physical activity (steps), and exercise. Participants are encouraged to regularly use health technology support tools customized to Hockey FIT. Minimally-supported phase: Participants are encouraged to continue with their healthy lifestyle behaviour changes and to regularly use the health technology support tools.
Study: NCT03042897

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Undergo DASH diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo in aerobic exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies